The Motley Fool··Prosper Junior BakinyIovance's Cell Therapy Bet: $1B Revenue Dream Amid Manufacturing Headwinds
Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.
IOVAbiotechoncology